Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 7;25(1):131.
doi: 10.1186/s13054-021-03548-y.

Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment

Maria Vincenza Mastrolia  1 , Edoardo Marrani  2 , Giovanni Battista Calabri  3 , Manuela L'Erario  4 , Ilaria Maccora  2 , Silvia Favilli  3 , Pier Paolo Duchini  4 , Ilaria Pagnini  2 , Gabriele Simonini  5
Affiliations
Comment

Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment

Maria Vincenza Mastrolia et al. Crit Care. .
No abstract available

Keywords: COVID 19; Kawasaki disease; PMIS-TS; SARS CoV-2 infection.

PubMed Disclaimer

Conflict of interest statement

The authors have no example conflicts of interest to disclose..

Figures

Fig. 1
Fig. 1
Trend of mean NT pro-BNP and troponin values in relation to PIMS-TS patients’ LVEF after starting anakinra (ANA)
Fig. 2
Fig. 2
Plasma levels of a C-reactive protein, b procalcitonin, c white blood cell counts, d ferritin, and e body temperature on day of admission to the intensive care unit (ICU), start of anakinra therapy, and until 8 days following cessation of anakinra. Results of 13 anakinra-treated patients of which data were available on multiple days after cessation of anakinra treatment are shown. Data are presented as geometric mean with 95% confidence intervals. Anakinra therapy was initiated 12 [7–17] and ceased 22 [18–25] days following ICU admission (median [IQR]). P-values were calculated using paired t-tests and mixed effect model analysis on log-transformed data. No inflammatory rebound effect was observed following cessation of anakinra therapy
See this image and copyright information in PMC

Comment on

References

    1. Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, Netea MG, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care. 2020;24(1):688. doi: 10.1186/s13054-020-03364-w. - DOI - PMC - PubMed
    1. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142(5):429–436. doi: 10.1161/CIRCULATIONAHA.120.048360. - DOI - PubMed
    1. Belhadjer Z, Auriau J, Méot M, Oualha M, Renolleau S, Houyel L, et al. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142(23):2282–2284. doi: 10.1161/CIRCULATIONAHA.120.050147. - DOI - PMC - PubMed
    1. Evans C, Davies P. SARS-CoV-2 paediatric inflammatory syndrome. Paediatr Child Health. 2021;31(3):110–115. doi: 10.1016/j.paed.2020.12.003. - DOI - PMC - PubMed
    1. Ramcharan T, Nolan O, Lai CY, Prabhu N, Krishnamurthy R, Richter AG, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020;41(7):1391–1401. doi: 10.1007/s00246-020-02391-2. - DOI - PMC - PubMed

Substances

Supplementary concepts